Merrimack Pharmaceuticals Inc. diskutieren

FDA genehmigt: Die Behandlung von Patienten mit metastasiertem Bauchspeicheldrüsenkrebs!

A speculative pick of the bunch with a small biotech concern called Merrimack Pharmaceuticals, which is at under $7.00 a share, about half its levels earlier this summer. The stock has declined despite the fact the FDA approved Merrimack's main drug candidate MM-398 known by its brand name "Onivyde" , in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy in late October.  Onivyde could eventually have $800 million in annual sales which is about equal to Merrimack's current market capitalization.

The company also has several promising compounds "MM-121, MM-141, MM-302" or "shots on goal" in early and mid-stage development as well. Merrimack recently raised $175 million to fund development of these drugs.

Four analysts have price targets on Merrimack in a relatively tight range of $13.00 to $15.00 a share.